2022-04-012023-03-312023-03-31false04401043BLUEPHARM LIMITED2023-10-1668209iso4217:GBPxbrli:pure044010432022-04-01044010432023-03-31044010432022-04-012023-03-31044010432021-04-01044010432022-03-31044010432021-04-012022-03-3104401043bus:SmallEntities2022-04-012023-03-3104401043bus:AuditExempt-NoAccountantsReport2022-04-012023-03-3104401043bus:FullAccounts2022-04-012023-03-3104401043bus:PrivateLimitedCompanyLtd2022-04-012023-03-3104401043core:WithinOneYear2023-03-3104401043core:AfterOneYear2023-03-3104401043core:WithinOneYear2022-03-3104401043core:AfterOneYear2022-03-3104401043core:ShareCapital2023-03-3104401043core:SharePremium2023-03-3104401043core:RevaluationReserve2023-03-3104401043core:OtherReservesSubtotal2023-03-3104401043core:RetainedEarningsAccumulatedLosses2023-03-3104401043core:ShareCapital2022-03-3104401043core:SharePremium2022-03-3104401043core:RevaluationReserve2022-03-3104401043core:OtherReservesSubtotal2022-03-3104401043core:RetainedEarningsAccumulatedLosses2022-03-3104401043core:LandBuildings2023-03-3104401043core:PlantMachinery2023-03-3104401043core:Vehicles2023-03-3104401043core:FurnitureFittings2023-03-3104401043core:OfficeEquipment2023-03-3104401043core:NetGoodwill2023-03-3104401043core:IntangibleAssetsOtherThanGoodwill2023-03-3104401043core:ListedExchangeTraded2023-03-3104401043core:UnlistedNon-exchangeTraded2023-03-3104401043core:LandBuildings2022-03-3104401043core:PlantMachinery2022-03-3104401043core:Vehicles2022-03-3104401043core:FurnitureFittings2022-03-3104401043core:OfficeEquipment2022-03-3104401043core:NetGoodwill2022-03-3104401043core:IntangibleAssetsOtherThanGoodwill2022-03-3104401043core:ListedExchangeTraded2022-03-3104401043core:UnlistedNon-exchangeTraded2022-03-3104401043core:LandBuildings2022-04-012023-03-3104401043core:PlantMachinery2022-04-012023-03-3104401043core:Vehicles2022-04-012023-03-3104401043core:FurnitureFittings2022-04-012023-03-3104401043core:OfficeEquipment2022-04-012023-03-3104401043core:NetGoodwill2022-04-012023-03-3104401043core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3104401043core:ListedExchangeTraded2022-04-012023-03-3104401043core:UnlistedNon-exchangeTraded2022-04-012023-03-3104401043core:MoreThanFiveYears2022-04-012023-03-3104401043core:Non-currentFinancialInstruments2023-03-3104401043core:Non-currentFinancialInstruments2022-03-3104401043dpl:CostSales2022-04-012023-03-3104401043dpl:DistributionCosts2022-04-012023-03-3104401043dpl:AdministrativeExpenses2022-04-012023-03-3104401043core:LandBuildings2022-04-012023-03-3104401043core:PlantMachinery2022-04-012023-03-3104401043core:Vehicles2022-04-012023-03-3104401043core:FurnitureFittings2022-04-012023-03-3104401043core:OfficeEquipment2022-04-012023-03-3104401043core:NetGoodwill2022-04-012023-03-3104401043core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3104401043dpl:GroupUndertakings2022-04-012023-03-3104401043dpl:ParticipatingInterests2022-04-012023-03-3104401043dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3104401043core:ListedExchangeTraded2022-04-012023-03-3104401043dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3104401043core:UnlistedNon-exchangeTraded2022-04-012023-03-3104401043dpl:CostSales2021-04-012022-03-3104401043dpl:DistributionCosts2021-04-012022-03-3104401043dpl:AdministrativeExpenses2021-04-012022-03-3104401043core:LandBuildings2021-04-012022-03-3104401043core:PlantMachinery2021-04-012022-03-3104401043core:Vehicles2021-04-012022-03-3104401043core:FurnitureFittings2021-04-012022-03-3104401043core:OfficeEquipment2021-04-012022-03-3104401043core:NetGoodwill2021-04-012022-03-3104401043core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3104401043dpl:GroupUndertakings2021-04-012022-03-3104401043dpl:ParticipatingInterests2021-04-012022-03-3104401043dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3104401043core:ListedExchangeTraded2021-04-012022-03-3104401043dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3104401043core:UnlistedNon-exchangeTraded2021-04-012022-03-3104401043core:NetGoodwill2023-03-3104401043core:IntangibleAssetsOtherThanGoodwill2023-03-3104401043core:LandBuildings2023-03-3104401043core:PlantMachinery2023-03-3104401043core:Vehicles2023-03-3104401043core:FurnitureFittings2023-03-3104401043core:OfficeEquipment2023-03-3104401043core:AfterOneYear2023-03-3104401043core:WithinOneYear2023-03-3104401043core:ListedExchangeTraded2023-03-3104401043core:UnlistedNon-exchangeTraded2023-03-3104401043core:ShareCapital2023-03-3104401043core:SharePremium2023-03-3104401043core:RevaluationReserve2023-03-3104401043core:OtherReservesSubtotal2023-03-3104401043core:RetainedEarningsAccumulatedLosses2023-03-3104401043core:NetGoodwill2022-03-3104401043core:IntangibleAssetsOtherThanGoodwill2022-03-3104401043core:LandBuildings2022-03-3104401043core:PlantMachinery2022-03-3104401043core:Vehicles2022-03-3104401043core:FurnitureFittings2022-03-3104401043core:OfficeEquipment2022-03-3104401043core:AfterOneYear2022-03-3104401043core:WithinOneYear2022-03-3104401043core:ListedExchangeTraded2022-03-3104401043core:UnlistedNon-exchangeTraded2022-03-3104401043core:ShareCapital2022-03-3104401043core:SharePremium2022-03-3104401043core:RevaluationReserve2022-03-3104401043core:OtherReservesSubtotal2022-03-3104401043core:RetainedEarningsAccumulatedLosses2022-03-3104401043core:NetGoodwill2021-04-0104401043core:IntangibleAssetsOtherThanGoodwill2021-04-0104401043core:LandBuildings2021-04-0104401043core:PlantMachinery2021-04-0104401043core:Vehicles2021-04-0104401043core:FurnitureFittings2021-04-0104401043core:OfficeEquipment2021-04-0104401043core:AfterOneYear2021-04-0104401043core:WithinOneYear2021-04-0104401043core:ListedExchangeTraded2021-04-0104401043core:UnlistedNon-exchangeTraded2021-04-0104401043core:ShareCapital2021-04-0104401043core:SharePremium2021-04-0104401043core:RevaluationReserve2021-04-0104401043core:OtherReservesSubtotal2021-04-0104401043core:RetainedEarningsAccumulatedLosses2021-04-0104401043core:AfterOneYear2022-04-012023-03-3104401043core:WithinOneYear2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:CostValuation2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3104401043core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3104401043core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3104401043core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3104401043core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3104401043core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3104401043bus:Director12022-04-012023-03-3104401043bus:Director22022-04-012023-03-31

BLUEPHARM LIMITED

Registered Number
04401043
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2023

BLUEPHARM LIMITED
Company Information
for the year from 1 April 2022 to 31 March 2023

Directors

SINGH, Fiona Margaret
SINGH, Sarvjit

Registered Address

8 Pirie Road
West Bergholt
Colchester
CO6 3TA

Registered Number

04401043 (England and Wales)
BLUEPHARM LIMITED
Balance Sheet as at
31 March 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Investment property5400,000400,000
400,000400,000
Current assets
Debtors3,009-
Cash at bank and on hand6,70610,820
9,71510,820
Creditors amounts falling due within one year6(73,938)(77,034)
Net current assets (liabilities)(64,223)(66,214)
Total assets less current liabilities335,777333,786
Creditors amounts falling due after one year7(283,950)(281,218)
Net assets51,82752,568
Capital and reserves
Called up share capital5,0005,000
Revaluation reserve46,99946,999
Profit and loss account(172)569
Shareholders' funds51,82752,568
The financial statements were approved and authorised for issue by the Board of Directors on 16 October 2023, and are signed on its behalf by:
SINGH, Sarvjit
Director
Registered Company No. 04401043
BLUEPHARM LIMITED
Notes to the Financial Statements
for the year ended 31 March 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Accounting policies
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Investment property policy
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognized in profit or loss.
4.Employee information

20232022
Average number of employees during the year22
5.Investment property

£
Fair value at 01 April 22400,000
At 31 March 23400,000
6.Creditors within one year

2023

2022

££
Bank borrowings and overdrafts3383,098
Taxation and social security-140
Other creditors71,80072,500
Accrued liabilities and deferred income1,8001,296
Total73,93877,034
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
7.Creditors after one year

2023

2022

££
Bank borrowings and overdrafts283,950281,218
Total283,950281,218